中国埃博拉病毒检测试剂获批 投入疫情防控

独秀文译青年

【原文标题】China drafts policy on emergency Ebola diagnosis, approves products

【中文标题】中国埃博拉病毒检测试剂获批 投入疫情防控

【文章来源】Adam Jourdan, 路透社

【原文链接】http://www.reuters.com/article/2014/11/28/us-ebola-china-idUSKCN0JC0SA20141128

(Reuters) - China has drafted a policy on the emergency use of diagnostic products for the Ebola virus disease and clinical trials, the country's drug regulator said on Friday, as the number of people affected globally by the epidemic nears 16,000.

中国食药监总局周五对外称，该局制定了紧急情况下埃博拉病毒检测试剂性能评估和临床试验政策。目前全球感染埃博拉病毒的人数接近16000。

In a brief statement, the China Food and Drug Administration (CFDA) said it had also approved three companies to produce Ebola diagnosis products for emergency reserve use.

据中国食药监总局介绍，三家企业生产的埃博拉病毒检测试剂产品已获批准用于疫情防控应急储备。

"These (products) provide key technological safeguards for China to diagnose the Ebola virus and defend against any epidemic situation," it said.

“它们为中国诊断埃博拉病毒和防控疫情提供了关键的技术保障。”

It did not add any further detail about the draft policy or say what the clinical trials relating to Ebola would involve.

该局没有透露更多关于政策的细节，也没有说明临床试验涉及的内容。

No cases of Ebola have been reported in China, but there are millions of Chinese nationals living in Africa, with around 10,000 in the worst affected countries - Sierra Leone, Guinea and Liberia.

中国目前尚未有埃博拉病例的报道，但居住在非洲的中国公民数以百万计，其中有大约一万人生活在埃博拉病情最严重三个非洲国家，分别是塞拉利昂、几内亚和利比里亚。

This has prompted concerns that Ebola could spread to China, which has previously faced severe outbreaks of infectious diseases such as SARS and bird flu.

在这种情况下，埃博拉就有可能传播到中国。中国曾爆发过SARS和禽流感等致命传染病。

The three companies named in the statement regarding diagnosis products are Da An Gene Co Ltd, Shenzhen Pu Rui Kang and Shanghai ZJ Bio-Tech Co Ltd.

被获批生产埃博拉检测试剂产品的三家公司分别为中山大学达安基因股份有限公司、深圳市普瑞康生物技术有限公司、上海之江生物科技股份有限公司。

Chinese drugmaker Sihuan Pharmaceutical Holdings Group Ltd is separately developing a treatment for Ebola with the country's military, and hopes to get fast-track approval for the drug.

在治疗方面，中国一家制药公司四环医药控股集团有限公司与一家军方机构达成协议，共同研发抗埃博拉药物，并希望药物审批能获得绿色通道。